Vaccine in development may treat latent herpes

Researchers recently discovered that a herpes vaccine that has been in development may be effective in treating the virus, even in its latent form.

When the researchers tested the vaccine on mice, the results showed that the vaccine effectively treated both herpes simplex virus strains (HSV-1 and HSV-2). The results surprisingly showed that the vaccine is also effective against the virus’s latent form.

As of today, there is still no herpes vaccine available to the public. The vaccine may be instrumental in the next step towards eliminating herpes from the world.

"Developing a herpes vaccine is one of the holy grails of infectious disease research,” researcher William Jacobs said. “We decided to take an approach that runs counter to most of the tactics used by other scientists - and we seem to have cracked the code. With herpes sores you continually get them. If our vaccine works in humans as it does in mice, administering it early in life could completely eliminate herpes latency."

Greg Bennett of the Center for the Biology of Chronic Disease (CBCD) which tested Novirin in two post-marketing clinical studies recommends those infected with HSV-1 of HSV-2 take this natural antiviral supplement.